Klebsiella pneumoniae causes infections in humans especially in immunocompromised patients. About 80 % of nosocomial infections caused by K. pneumoniae are due to multidrug-resistant strains. The emergence of antibiotic-resistant bacterial strains necessitates the exploration of alternative antibacterial therapies, which led our group to study the ability of bacterial viruses (known as bacteriophages or simply phages) to treat mice challenged with K. pneumoniae. Phage SS specific for K. pneumoniae B5055 was isolated and characterized, and its potential as a therapeutic agent was evaluated in an experimental model of K. pneumoniae-mediated lobar pneumonia in mice. Mice were challenged by intranasal (i.n.) inoculation with bacteria (108 c.f.u. ml−1). A single intraperitoneal injection of 1010 p.f.u. ml−1 phage administered immediately after i.n. challenge was sufficient to rescue 100 % of animals from K. pneumoniae-mediated respiratory infections. Administration of the phage preparation 3 h prior to i.n. bacterial challenge provided significant protection in infected mice, while even 6 h delay of phage administration after the induction of infection rendered the phage treatment ineffective. The results of this study therefore suggest that the timing of starting the phage therapy after initiation of infection significantly contributes towards the success of the treatment.
BogovazovaG. G.,
VoroshilovaN. N.,
BondarenkoV. M.1991; The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection. Zh Mikrobiol Epidemiol Immunobiol 4:5–8 (in Russian
BogovazovaG. G.,
VoroshilovaN. N.,
GorbatkovaG. A.,
BondarenkoV. M.,
KazakovaT. B.,
MamleevaA. G.,
SirnovV. D.,
GlukharevI. A.,
ErastovaE. I.other authors1992; Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages. Zh Mikrobiol Epidemiol Immunobiol 3:30–33 (in Russian
CervenyK. E.,
DePaolaA.,
DuckworthD. H.,
GuligP. A.2002; Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun 70:6251–6262[CrossRef]
ChhibberS.,
BajajJ.1995; Polysaccharide iron regulated cell surface protein conjugated vaccine: its role in protection against Klebsiella pneumoniae induced lobar pneumonia. Vaccine 13:179–189[CrossRef]
GoodridgeL.,
GallacciA.,
GriffithsM. W.2003; Morphological, host range and genetic characterization of two coliphages. Appl Environ Microbiol 69:5364–5371[CrossRef]
GraybillJ. R.,
MarshallL. W.,
CharacheP.,
WallaceC. K.,
MelvinV. B.1973; Nosocomial pneumonia. A continuing major problem. Am Rev Respir Dis 108:1130–1140
HansenD. S.,
GottschauA.,
KolmosH. J.1977; Epidemiology of Klebsiella bacteraemia: a case control study using Escherichia coli bacteraemia as control. J Hosp Infect 38:119–132
LevinB. R.,
BullJ. J.1996; Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Nat 147:881–898[CrossRef]
MeyerK. S.,
UrbanC.,
EaganJ. A.,
BergerB. J.,
RahalJ. J.1993; Nosocomial outbreak of Klebsiella infection resistant to late generation cephalosporins. Ann Intern Med 119:353–358[CrossRef]
NishiT.,
TsuchiyaK.1980; Therapeutic effects of cefotiam and cefazolin on experimental pneumonia caused by Klebsiella pneumoniae DT-S in mice. Antimicrob Agents Chemother 18:549–556[CrossRef]
YadavV.,
SharmaS.,
HarjaiK.,
MohanH.,
ChhibberS.2003; Induction & resolution of lobar pneumonia following intranasal instillation with Klebsiella pneumoniae in mice. Indian J Med Res 118:47–52